Table 4.
Changes in knee-joint functions and locomotor functions at each time point in subjects with mild-to-severe knee pain at baselinea
| Variables | Values at each time pointb
|
Two-way ANOVA (group × time) P-value | ||||
|---|---|---|---|---|---|---|
| Baseline | Week 4 | Week 8 | Week 12 | Week 16 | ||
| JKOM | ||||||
| (I) VAS score for knee pain (mm) | ||||||
| GCQID | 41.5±4.0 | 31.2±4.3 | 19.9±2.9** | 15.4±4.4** | 9.9±3.4** | 0.490 |
| Placebo | 40.0±3.1 | 28.6±3.9* | 22.4±3.5** | 18.5±3.7** | 16.4±3.0** | |
| (II–V) Total score (points) | ||||||
| GCQID | 17.6±2.5 | 14.3±2.5 | 10.3±1.5* | 10.7±2.0** | 9.2±1.7** | 0.169 |
| Placebo | 15.2±1.3 | 13.7±1.6 | 13.3±1.6 | 12.2±1.7 | 10.6±1.2 | |
| VAS score for pain on walking (mm) | ||||||
| GCQID | 33.3±4.3 | 22.2±4.3* | 14.3±3.4** | 12.0±3.9** | 8.7±3.8** | 0.067 |
| Placebo | 24.5±3.0 | 20.0±3.7 | 17.9±3.4* | 16.6±3.4* | 9.6±2.4** | |
| Normal walking speed (m/s) | ||||||
| GCQID | 1.26±0.04 | 1.32±0.04* | 1.37±0.04** | 0.095 | ||
| Placebo | 1.25±0.03 | 1.28±0.03 | 1.30±0.03* | |||
| Knee extensor strength (% body weight)c | ||||||
| GCQID | 93.4±6.7 | 108.4±5.3**,§ | 109.8±5.6** | 0.330 | ||
| Placebo | 81.5±7.6 | 88.0±7.3 | 92.0±7.8** | |||
Notes:
a
GCQID group (n=23) and placebo group (n=25).
b
Values are expressed as mean ± standard error.
c
Knee-extensor strength was measured in both knees and expressed as total strength of both knees.
*
P<0.05 and
**
P<0.01 compared with values at baseline.
§
P<0.05 compared with placebo.
Abbreviations: ANOVA, analysis of variance; GCQID, glucosamine hydrochloride, chondroitin sulfate, type II collagen peptides, quercetin glycosides, imidazole peptides, and vitamin D; JKOM, Japanese Knee Osteoarthritis Measure; VAS, visual analog scale.